Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

4082 - Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Riyaz Shah

Citation

Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260

Authors

R. Shah1, N. Girard2, S.P. Nagar3, F. Griesinger4, J. Roeper4, K. Davis3, N. Bakker5, B. Thakrar5, A. Taylor5, J. Feliciano6

Author affiliations

  • 1 Oncology, Kent Oncology Centre, Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, ME16 9QQ - Maidstone/GB
  • 2 Thorax Institute Curie Montsouris, Institut Curie, 75005 - Paris/FR
  • 3 Health Economics Group, RTI Health Solutions, Research Triangle Park, Durham/US
  • 4 Department Of Hematology And Oncology, Pius Hospital, University of Oldenburg, 26121 - Oldenburg/DE
  • 5 Oncology Business Unit, AstraZeneca, Cambridge/GB
  • 6 Thoracic Oncology Program, Johns Hopkins Bayview Medical Center,, Baltimore/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4082

Background

EGFR-TKIs are the preferred 1L therapy for pts with EGFRm metastatic NSCLC. However, treatment and survival in this population with 2L therapy and beyond are not well defined in the RW setting. To address this, we analysed RW cohort data in the USA, UK, Germany and France.

Methods

A retrospective chart review was conducted for 472 pts with EGFRm NSCLC receiving a 1L 1G / 2G EGFR-TKI (1 Jan 2015–31 Dec 2017). Data on 1L and 2L treatment and progression after 1L initiation (defined by clinical progression, start of 2L treatment or death before 2L treatment initiation) were extracted. 1L progression-free (PFS) and overall survival (OS) were estimated via Kaplan–Meier methods.

Results

Baseline characteristics at 1L: median age 62 yrs; 43% female; 61% current/former smokers; 60% Caucasian; 76% Exon 19 deletion. 1L EGFR-TKI treatments: 44% afatinib; 36% erlotinib; 21% gefitinib. Median duration of overall follow-up from start of 1L was 19.9 months (mo; range 0.3–50.3). Of 472 pts, 344 (73%) progressed on 1L treatment, including 158 who died during follow-up. 128 (27%) pts did not progress: 86 (18%) remained on 1L treatment and 42 (9%) pts discontinued 1L treatment before follow-up end. Median 1L PFS (95% CI) was 14.5 (13.3, 15.6) mo and median OS (95% CI) from start of 1L was 34.6 (29.5, 45.5) mo. Of 344 pts with 1L progression, 255 (74%) were tested for T790M; 129 (38%) were positive, of whom 97 received osimertinib (75%). Of 126 pts testing negative, 17 (13%) received osimertinib. Of 344 pts with 1L progression, 258 (75%) received 2L treatment, osimertinib-containing regimens being most common (n = 109/258, 42%). For 86 (25%) pts with 1L progression but no 2L treatment, 73 (85%) died and 13 (15%) were alive at follow-up end.

Conclusions

25% of pts progressing on 1L EGFR-TKIs did not receive 2L treatment (due to death in most cases). Furthermore, 25% of pts who progressed on 1L treatment and tested T790M positive did not receive osimertinib. Findings indicate that rates of resistance mutation testing and utilisation of effective EGFRm NSCLC therapies may be suboptimal.

Clinical trial identification

Editorial acknowledgement

Robert Harrison, PhD, of iMed Comms, Macclesfield, UK, an Ashfield Company; funded by AstraZeneca.

Legal entity responsible for the study

AstraZeneca.

Funding

AstraZeneca.

Disclosure

R. Shah: Honoraria (self), Travel / Accommodation / Expenses: Boehringer Ingelheim, Roche, AstraZeneca. N. Girard: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): AstraZeneca, Boehringer Ingelheim. S.P. Nagar: Advisory / Consultancy, Employee of RTI-HS who provides consulting services to AstraZeneca: AstraZeneca. F. Griesinger: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Celgene, Lilly, Roche, Merck Sharp & Dohme, Bristol-Myers Squibb, Takeda, Siemens; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AbbVie. J. Roeper: Honoraria (institution): Boehringer Ingelheim, Roche, AstraZeneca. K. Davis: Research grant / Funding (institution): AstraZeneca, Novartis, Celgene, Sanofi, Pfizer, Amgen. N. Bakker: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. B. Thakrar: Full / Part-time employment: AstraZeneca. A. Taylor: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. All other authors have declared no conflicts of interest. J. Feliciano: Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: Genentech; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Takeda; Honoraria (self), Advisory / Consultancy: Eli Lilly.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.